A- A A+

Schachmatt für Hepatitis B-Viren in der Leber

Forschenden des Helmholtz Zentrums München und der Technischen Universität München ist es in Zusammenarbeit mit Kollegen des Universitätsklinikum Hamburg Eppendorf und des Universitätsklinikum Heidelberg im Tiermodell erstmals gelungen, eine chronische Infektion mit dem Hepatitis-B-Virus zu besiegen. Das Team hat in seiner Arbeit gezeigt, dass eine T-Zelltherapie zu einer echten Heilung führen kann. Bislang war es nicht möglich, das Virus komplett zu kontrollieren. Die Veröffentlichung ist jetzt in der Zeitschrift Journal of Clinical Investigation erschienen. (Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt, 11.06.2019)

https://idw-online.de/de/news717247

Hepatitis C Late Relapse in Patients With Directly Acting Antiviral-related Sustained Virological Response at Week 12

Mariantonietta Pisaturo; Carmine Minichini; Mario Starace; Mara Caroprese; Margherita Macera; Giuseppina Brancaccio; Stefania De Pascalis; Antonella Santonicola; Alfonso Galeota Lanza; Rosa Zampino; Gaetano Cotticelli; Evangelista Sagnelli; Giovanni Battista Gaeta; Nicola Coppola

Liver International. 2019;39(5):844-853

https://www.medscape.com/viewarticle/912573

PLUS-Gesundheitsinitiative Hepatitis C – „Mehr“ Versorgung von Suchtbetroffenen

(Die PLUS-Projekte wurden durch finanzielle Unterstützung der Firma AbbVie Deutschland GmbH & Co. KG ermöglicht.)

https://www.hcvversorgungplus.de/

Hepatitis C und Sucht - Im Gespräch mit Substitutionsmedizinerin Dr. med. Petra Pflaum, Ludwigshafen 

Im Rahmen der PLUS-Gesundheitsinitiativen Hepatitis C arbeitet die Ärztin Dr. Petra Pflaum mit Partnern daran, die Versorgungssituation von Menschen mit (ehemaligem) Drogengebrauch zu verbessern. Im Interview schildert sie, wie sie sich engagiert und was sie bewegt. (hiv&more online, 28.05.2019 – mit freundlicher Unterstützung von AbbVie Deutschland GmbH & Co. KG)

https://www.hivandmore.de/aktuell/2019-05/hepatitis-c-und-sucht.shtml

Hepatitis C-Eliminierung: Rein in die Drogenszene

Die Eliminierung von Hepatitis C bis 2030 ist ein hehres Ziel. Doch wer es erreichen will, muss von den klassischen Wegen abweichen – und tief in die Drogenszene eintauchen. (Pharma Fakten, 13.05.2019)

https://www.pharma-fakten.de/news/details/770-hepatitis-c-eliminierung-rein-in-die-drogenszene/

Australien. World first program aims to eliminate hepatitis C among people who inject drugs

The inaugural symposium of the world first research program ASCEND was held at UNSW Sydney on Monday, 13 May.

ASCEND is designed to improve access to hepatitis C treatment for people who inject drugs and potentially eliminate the virus among this population.

The five-year research program is being run jointly by The National Drug and Alcohol Research Centre (NDARC) and The Kirby Institute at UNSW Sydney and is funded by a $9 million National Health and Medical Research Centre (NHMRC) program grant which commenced in January 2019. (University of South Wales, Sydney; NDARC – National Drug and Alcohol Research Center, Australien, 28.05.2019)

https://ndarc.med.unsw.edu.au/news/world-first-program-aims-eliminate-hepatitis-c-among-people-who-inject-drugs

Integrated care for methadone maintenance patients with hepatitis C virus infection.

Tai CM, Yen YC, Bair MJ, Tseng CH, Chang TT, Huang CF, Yeh ML, Dai CY, Chuang WL, Yu ML, Huang JF.

Kaohsiung J Med Sci. 2019 May 14. doi: 10.1002/kjm2.12086. 

https://onlinelibrary.wiley.com/doi/full/10.1002/kjm2.12086

Opioid agonist treatment dosage and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugs.

Artenie AA, Minoyan N, Jacka B, Høj S, Jutras-Aswad D, Roy É, Gauvin L, Zang G, Bruneau J.

CMAJ. 2019 Apr 29;191(17):E462-E468. doi: 10.1503/cmaj.181506.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488472/

Prevalence of and risk factors for hepatitis C virus antibody among people who inject drugs in Cambodia: a national biological and behavioral survey 

Siyan Yi, Phalkun Mun, Pheak Chhoun, Navy Chann, Sovannary Tuot and Gitau Mburu

Harm Reduction Journal 2019, 16:29 

https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-019-0299-1

Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries

Mojca Maticic, Jerneja Videcnik Zorman, Sergeja Gregorcic, Eberhard Schatz and Jeffrey V. Lazarus

Harm Reduction Journal 2019, 16:32, Published on: 9 May 2019, doi.org/10.1186/s12954-019-0303-9

https://harmreductionjournal.biomedcentral.com/track/pdf/10.1186/s12954-019-0303-9

Gilead startet Programm zur Förderung der Elimination von Hepatitis C - Geeignete Organisationen werden mit bis zu 100.000 Pfund über 12 Monate unterstützt

Das neue Förderprogramm „COMMIT“ von Gilead Sciences Inc im Rahmen der LEGA-C Initiative (Local Elimination programs leading to Global Action in HCV) unterstützt Projekte mit dem Ziel der Elimination von Hepatitis C mit bis zu 100.000 Pfund über 12 Monate. Die Organisation muss als Non-Profit-Organisation klassifiziert sein, mit Sitz in Europa, Australien oder dem Nahen Osten. Außerdem muss ein Ziel der Organisation „Public Health“ sein.

Speziell inkludiert sind auch kleinere Programme die nur eine kleine Population betreffen. Zum Beispiel Programme speziell für Gefängnisinsassen, Programme begrenzt auf bestimmte Gebiete oder Städte, Programme für Koinfektionen mit Hepatitis C und HIV, und weitere. 

Bewerbungsfrist für eine Förderung ist der 28. Juni 2019. (hepatitisandmore.de, 04.04.2019

https://www.hepatitisandmore.de/aktuell/2019-04/gilead-startet-programm-zur-foerderung-der-elimination-von-hepatitis-c.shtml

8th International Conference on Hepatitis Care in Substance Users

Le Westin, Montréal, Canada, 11 - 13 September 2019

http://inhsu2019.com/

Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy.

Janjua NZ, Darvishian M, Wong S, Yu A, Rossi C, Ramji A, Yoshida EM, Butt ZA, Samji H, Chong M, Chapinal N, Cook D, Alvarez M, Tyndall M, Krajden M; British Columbia Hepatitis Testers Cohort Team.

Hepatol Commun. 2019 Jan 10;3(4):478-492. doi: 10.1002/hep4.1307.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442698/

Significant HbA1c Lowering in Patients Achieving a Hepatitis C Virus Cure.

Rife K, Lyman A, LeClerc-Kamieniecki S, Falck-Ytter C, Pascuzzi K, Burant CJ, Falck-Ytter Y.

Fed Pract. 2019 Mar;36(Suppl 2):S26-S32.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6453605/

All Patients With Advanced Fibrosis Should Continue to Be Screened for Hepatocellular Carcinoma After Sustained Virological Response of Hepatitis C Virus.

Khan R, Velpari S, Koppe S.

Clin Liver Dis (Hoboken). 2018 Dec 14;12(5):137-139. doi: 10.1002/cld.707.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385927/

The link between hepatitis C virus and diabetes mellitus: Improvement in insulin resistance after eradication of hepatitis C virus.

Hum J, Jou JH.

Clin Liver Dis (Hoboken). 2018 Apr 6;11(3):73-76. doi: 10.1002/cld.694. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385943/

Management Approaches to Hepatitis B Virus Vaccination Nonresponse.

Yanny B, Konyn P, Najarian LM, Mitry A, Saab S.

Gastroenterol Hepatol (N Y). 2019 Feb;15(2):93-99.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469266/

Alpha-fetoprotein to transaminase ratio is related to higher diagnostic efficacy for hepatocellular carcinoma.

Liu X, Meng J, Xu H, Niu J.

Medicine (Baltimore). 2019 Apr;98(17):e15414. doi: 10.1097/MD.0000000000015414.

https://journals.lww.com/md-journal/fulltext/2019/04260/Alpha_fetoprotein_to_transaminase_ratio_is_related.94.aspx

Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents.

Hsu WF, Lai HC, Su WP, Lin CH, Chuang PH, Chen SH, Chen HY, Wang HW, Huang GT, Peng CY.

BMC Gastroenterol. 2019 Apr 27;19(1):63. doi: 10.1186/s12876-019-0973-5.

https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-019-0973-5

Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.

Buggisch P, Wursthorn K, Stoehr A, Atanasov PK, Supiot R, Lee J, et al. (2019) 

PLoS ONE 14(4): e0214795. doi.org/10.1371/journal.pone.0214795

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0214795

Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy-Data From the German Hepatitis C-Registry (DHC-R).

Christensen S, Buggisch P, Mauss S, Böker KH, Müller T, Klinker H, Zimmermann T, Serfert Y, Weber B, Reimer J, Wedemeyer H; German Hepatitis C-Registry.

Subst Abuse. 2019 Mar 28;13:1178221819835847. doi: 10.1177/1178221819835847.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440029/

Marijuana is not associated with progression of hepatic fibrosis in liver disease: a systematic review and meta-analysis.

Farooqui MT, Khan MA, Cholankeril G, Khan Z, Mohammed Abdul MK, Li AA, Shah N, Wu L, Haq K, Solanki S, Kim D, Ahmed A.

Eur J Gastroenterol Hepatol. 2019 Feb;31(2):149-156. doi: 10.1097/MEG.0000000000001263.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467701/

Neuropsychiatric Symptoms in Hepatitis C Patients Resemble Those of Patients With Autoimmune Liver Disease but Are Different From Those in Hepatitis B Patients

Meike Dirks; Kim Haag; Henning Pflugrad; Anita B. Tryc; Ramona Schuppner; Heiner Wedemeyer; Andrej Potthoff; Hans L. Tillmann; Kajetan Sandorski; Hans Worthmann; Xiaoqi Ding; Karin Weissenborn

J Viral Hepat. 2019;26(4):422-431

https://www.medscape.com/viewarticle/910688

Europa. Slight decline in hepatitis C diagnoses in 2017

European surveillance data show a 10% decrease in newly reported hepatitis C cases between 2016 and 2017. However, with more than 31 000 recorded cases in 2017, diagnoses remain at a high level in the European Union and European Economic Area (EU/EEA). In addition, variation in national testing practices and widespread under-reporting of diagnosed cases do not provide an accurate picture of the true epidemiological burden. (European Centre for Disease Prevention and Control, Schweden, 29.03.2019)

https://ecdc.europa.eu/en/news-events/slight-decline-hepatitis-c-diagnoses-2017

Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey

Andrew Scheibe, Katherine Young, Lorraine Moses, Rudolph L. Basson, Anna Versfeld, C. Wendy Spearman, Mark W. Sonderup, Nishi Prabdial-Sing, Jack Manamela, Adrian J. Puren, Kevin Rebe and Harry Hausler

Harm Reduction Journal 2019, 16:28, doi.org/10.1186/s12954-019-0298-2

https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-019-0298-2

Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial.

Akiyama MJ, Norton BL, Arnsten JH, Agyemang L, Heo M, Litwin AH.

Ann Intern Med. 2019 Apr 9. doi: 10.7326/M18-1715.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/30959528

Hepatitis C transmission in young people who inject drugs: Insights using a dynamic model informed by state public health surveillance.

Gicquelais RE, Foxman B, Coyle J, Eisenberg MC.

Epidemics. 2019 Feb 28. pii: S1755-4365(18)30103-8. doi: 10.1016/j.epidem.2019.02.003.

https://www.sciencedirect.com/science/article/pii/S1755436518301038

Epidemiology and management of hepatitis C virus infections in immigrant populations.

Coppola N, Alessio L, Onorato L, Sagnelli C, Macera M, Sagnelli E, Pisaturo M.

Infect Dis Poverty. 2019 Mar 15;8(1):17. doi: 10.1186/s40249-019-0528-6. Review.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419370/

Direct-Acting Antiviral Treatment Failure Among Hepatitis C and HIV-Coinfected Patients in Clinical Care.

Rossi C, Young J, Martel-Laferrière V, Walmsley S, Cooper C, Wong A, Gill MJ, Klein MB; Canadian Co-Infection Cohort Investigators .

Open Forum Infect Dis. 2019 Feb 13;6(3):ofz055. doi: 10.1093/ofid/ofz055. 

https://www.ncbi.nlm.nih.gov/pubmed/30882016

Neural-network analysis of socio-medical data to identify predictors of undiagnosed hepatitis C virus infections in Germany (DETECT).

Reiser M, Wiebner B, Hirsch J; German Liver Foundation.

J Transl Med. 2019 Mar 19;17(1):94. doi: 10.1186/s12967-019-1832-4.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425680/